Celldex Therapeutics Hits Day High with 24% Surge in Stock Price

Celldex Therapeutics, Inc. has experienced significant movement in its stock today, achieving a notable intraday high of USD 31.00. The stock surged by 24.07% on February 25, 2026, outperforming the S&P 500, which saw a modest gain of 0.69% during the same period. Over the past week, Celldex has shown a remarkable performance with a 34.0% increase, while its one-month performance stands at 18.9%. Despite these short-term gains, the company has faced challenges in its long-term growth trajectory. Over the last five years, net sales have declined at an annual rate of -10.47%, and operating profit has seen a significant drop of -223.98%. The latest financial results indicate a concerning trend, with net sales for the half-year at USD 0.73 million, reflecting an 87.17% decrease. Celldex Therapeutics operates within the Pharmaceuticals & Biotechnology sector and holds a market capitalization of USD 1,530 million. The company’s financial metrics, including a return on equity of -37.52% and a price-to-book ratio of 2.56, highlight the ongoing challenges it faces in the market.